SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
- Seasoned team to drive forward pivotal trial for patients suffering from Tenosynovial Giant Cell Tumours (TGCT)
- Follows recent appointments of Professor Ton Logtenberg as non-executive Chairman and Ray Barlow as Chief Executive Officer
News provided by
Share this article
DUBLIN, Aug. 3, 2021 /PRNewswire/
SynOx Therapeutics Limited ( SynOx or the Company ), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumours (TGCT), today announces the appointments of Axel Mescheder, MD as Chief Medical Officer and Broes Naeye, PhD as Chief Technology Officer, as it accelerates activities to support a registrational trial of emactuzumab in the USA and EU.
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
- First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2
- Evaluation of Cristal s CliCr® and Intravacc s OMV technology
News provided by
Share this article
, a world leader in translational research and development of vaccines, and Cristal Therapeutics, a technology leader in enabling safer and more effective therapeutics, today announced a strategic collaboration to develop novel vaccine programs against human diseases with the initial candidate targeting COVID-19.
(PRNewsfoto/Intravacc B.V.)
Under the terms of the agreement, Cristal Therapeutics and Intravacc will collaborate with an initial focus on generating a CriVac